Literature DB >> 15452077

Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC).

Jill Yardley1, Bart P Leroy, Niki Hart-Holden, Bart A Lafaut, Bart Loeys, Ludwine M Messiaen, Rahat Perveen, M Ashwin Reddy, Shomi S Bhattacharya, Elias Traboulsi, Diana Baralle, Jean-Jacques De Laey, Bernard Puech, Philippe Kestelyn, Anthony T Moore, Forbes D C Manson, Graeme C M Black.   

Abstract

PURPOSE: To investigate the genetic basis of autosomal dominant vitreoretinochoroidopathy (ADVIRC), a rare, inherited retinal dystrophy that may be associated with defects of ocular development, including nanophthalmos.
METHODS: A combination of linkage analysis and DNA sequencing in five families was used to identify disease-causing mutations in VMD2. The effect of these mutations on splicing was assessed using a minigene system.
RESULTS: Three pathogenic sequence alterations in VMD2 were identified in five families with nanophthalmos associated with ADVIRC. All sequences showed simultaneous missense substitutions and exon skipping.
CONCLUSIONS: VMD2 encodes bestrophin, a transmembrane protein located at the basolateral membrane of the RPE, that is also mutated in Best macular dystrophy. We support that each heterozygous affected individual produces three bestrophin isoforms consisting of the wild type and two abnormal forms: one containing a missense substitution and the other an in-frame deletion. The data showed that VMD2 mutations caused defects of ocular patterning, supporting the hypothesized role for the RPE, and specifically VMD2, in the normal growth and development of the eye.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452077     DOI: 10.1167/iovs.04-0550

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  76 in total

1.  SOX9, through interaction with microphthalmia-associated transcription factor (MITF) and OTX2, regulates BEST1 expression in the retinal pigment epithelium.

Authors:  Tomohiro Masuda; Noriko Esumi
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  Clinical utility gene card for: BEST1-related dystrophies (Bestrophinopathies).

Authors:  Simon C Ramsden; Alice E Davidson; Bart P Leroy; Anthony T Moore; Andrew R Webster; Graeme C M Black; Forbes D C Manson
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

Review 3.  Bestrophins and retinopathies.

Authors:  Qinghuan Xiao; H Criss Hartzell; Kuai Yu
Journal:  Pflugers Arch       Date:  2010-03-28       Impact factor: 3.657

Review 4.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

5.  BEST1-related autosomal dominant vitreoretinochoroidopathy: a degenerative disease with a range of developmental ocular anomalies.

Authors:  A Vincent; C McAlister; C Vandenhoven; E Héon
Journal:  Eye (Lond)       Date:  2010-11-12       Impact factor: 3.775

6.  Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies.

Authors:  Karina E Guziewicz; Julianna Slavik; Sarah J P Lindauer; Gustavo D Aguirre; Barbara Zangerl
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

Review 7.  [Genetic diseases of the retinal pigment epithelium].

Authors:  M N Preising; B Lorenz
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

Review 8.  RNA Biology in Retinal Development and Disease.

Authors:  Lina Zelinger; Anand Swaroop
Journal:  Trends Genet       Date:  2018-01-31       Impact factor: 11.639

9.  Rescue of volume-regulated anion current by bestrophin mutants with altered charge selectivity.

Authors:  Li-Ting Chien; H Criss Hartzell
Journal:  J Gen Physiol       Date:  2008-11       Impact factor: 4.086

10.  Suppression of Ca2+ signaling in a mouse model of Best disease.

Authors:  Youwen Zhang; J Brett Stanton; Jiang Wu; Kuai Yu; H Criss Hartzell; Neal S Peachey; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.